Wells Fargo raised the firm’s price target on Elevance Health (ELV) to $424 from $403 and keeps an Overweight rating on the shares. For managed care organizations, the firm is most constructive on Medicare Advantage with uncertainty high for Medicaid/Exchanges. Wells sees a more difficult backdrop for hospitals in 2026 as post-COVID tailwinds wane and legislative risks near. Distributor debate remains revisions vs. multiples.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Trump says he will meet with 14 health insurers in a few days
- Elevance Health price target raised to $431 from $412 at Bernstein
- Elevance Health price target raised to $404 from $385 at Barclays
- Trump Trade: Trump strikes deals with nine drugmakers to cut prices
- The Week That Was, The Week Ahead: Macro & Markets, Dec. 20